WO1996041878A1 - Nucleic acid molecule and its uses in determining pathogenicity of staphylococcus - Google Patents
Nucleic acid molecule and its uses in determining pathogenicity of staphylococcus Download PDFInfo
- Publication number
- WO1996041878A1 WO1996041878A1 PCT/AU1996/000353 AU9600353W WO9641878A1 WO 1996041878 A1 WO1996041878 A1 WO 1996041878A1 AU 9600353 W AU9600353 W AU 9600353W WO 9641878 A1 WO9641878 A1 WO 9641878A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- acid molecule
- seq
- aureus
- isolated nucleic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present invention relates to an isolated nucleic acid, reagents, a method of determining whether a Staphylococcus strain is pathogenic and tests for use in the method.
- Staphylococcus particularly S. aureus are significant pathogens in hospitals and in general practice, yet these organisms are often found harmlessly associated with humans (Noble & White, 1983). S. aureus, for example, is among the five most commonly reported pathogens (11.2%) in hospitals (Jarvis & Martone, 1992; Schaberg et al, 1991). The organism appears to show considerable genetic malleability (Novick, 1993), with a capacity to develop resistance and probably to vary its virulence (Skurray et al, 1988; Amabiel-Cuevas & Chicurel, 1992). Methicillin-resistant S.
- MRS A Musser & Kapur, 1992; Stewart et al, 1993.
- the population structure of MRSA and pathogenic populations of Staphylococcus aureus have been examined using a variety of techniques including enzyme electrophoretic typing (Musser et al, 1990; Musser & Selander, 1990) and restriction fragment length polymo ⁇ hisms (RFLP) (El-Adhami et al, 1991; Stewart et al, 1993). Analysis of Staphylococci and other bacteria (eg. Neisseria meningitidis, Haemophilus influenzae, Salmonella spp, etc.) indicate that resistant and pathogenic populations are clonal in structure.
- MSSA methicillin-sensitive Staphylococcus aureus
- non- clinical (or community) S. aureus isolates show a great degree of genetic diversity (El- Adhami, 1991; El-Adhami & Stewart, manuscript in preparation).
- Community S. aureus isolates are a population in which selection pressure for virulence and resistance may not occur. RFLP analysis showed that these isolates were not closely related to each other or to the resistant types (ie. non-clonal in structure).
- the inventors identified and isolated genetic sequences which are indicative of infection of a host organism, tissue or cell by a pathogenic Staphylococcus aureus strain or a strain which is related to a pathogenic strain or belonging to the same clonal group as a pathogenic strain.
- the isolated genetic sequences provide the means by which pathogenic infection of a host animal by S. aureus may be determined in a rapid, convenient assay.
- the isolated genetic sequences of the invention provide the means for development of vaccines for the prophylactic treatment of a host organism, tissue or cell which is capable of being infected by a pathogenic strain of S. aureus.
- a first aspect of the present invention provides an isolated nucleic acid molecule which is indicative of a pathogenic Staphylococcus aureus, wherein said molecule is obtainable from a pathogenic S. aureus and present at high frequency in pathogenic isolates of S. aureus.
- the isolated nucleic acid molecule is further characterised as being either not present or present at a low frequency in one or more commensal isolates of S. aureus.
- the isolated nucleic acid molecule of the invention is further characterised as comprising at least one copy of the repeated nucleotide sequence motif:
- the repeated nucleotide sequence motif is repeated at least two times and more preferably still, at least four times and still more preferably at least six times in the nucleic acid molecule of the invention.
- the nucleic acid molecule comprises a sequence of nucleotides or is complementary to a sequence of nucleotides which is at least 40% identical to the sequence set forth in SEQ ID NO: 1 or a homologue, analogue or derivative thereof.
- ID NO: 1 is at least 50%. Even more particularly preferred, the percentage similarity is at least
- the invention provides an isolated nucleic acid molecule which is indicative of a pathogenic Staphylococcus aureus, wherein said molecule is obtainable from a pathogenic S. aureus and present at high frequency in pathogenic isolates of S. aureus and comprises the sequence set forth in SEQ ID NO: 1 or a complementary sequence, homologue, analogue or derivative thereof.
- sequence shown in SEQ ID NO: 1 relates to a strain-specific or species-specific gene sequence isolated from the clmically-significant, methicillin-sensitive Staphylococcus aureus strain 8325-4 (i.e. ISP8, Patel et al. , 1989).
- the sequence set forth in SEQ ID NO: 1 or a homologue, analogue or derivative thereof is present at a high frequency in other pathogenic strains of S. aureus, but is present at a low frequency only in commensal isolates of S. aureus, as shown in the examples inco ⁇ orated herein.
- isolated nucleic acid molecule means that the nucleic acid molecule has been purified away from other nucleic acids, proteinaceous and non- proteinaceous components with which it is normally associated.
- nucleic acid molecule refers to a molecule made up of natural or synthetic purines and pyrimidines.
- the molecule may be DNA such as genomic DNA, cDNA or chemically-synthesised DNA or alternatively, RNA such as mRNA, tRNA, rRNA or synthetic RNA.
- the nucleic acid molecule may be in single or double stranded, linear, covalently closed or circular form. Unless otherwise indicated the nucleic acid bases described herein are designated according to the IUPAC code.
- pathogenic isolate As used herein, the term "pathogenic isolate”, “pathogenic strain” or similar term shall be taken to refer to any strain of Staphylococcus aureus which is capable of inducing an infection in a host organism, tissue or cell, for example certain methicillin-sensitive and methicillin-resistant strains.
- the host for a pathogenic S. aureus is a whole organism or multicellular tissue or organ
- infection of the host by a pathogenic S. aureus is characterised by a disease state therein (i.e. a disturbance in the normal functioning of the host).
- the host is a cell, including a cell culture or non-differentiated mass of cells, infection by a pathogenic S.
- aureus is characterised by a disturbance in the normal growth of the cell or cell culture or non-differentiated mass of cells. Alternatively, the infection may be visually apparent in the cell or cell culture or cell mass.
- "disease” shall be taken to include a disturbance in the growth of a cell or cell culture or cell mass, or a visually-apparent bacterial infection in a cell or cell culture or cell mass.
- a pathogenic strain shall also be taken to refer to a strain which is likely to be pathogenic because it is closely related at the genetic level to a pathogenic strain, for example belonging to the same clonal group.
- pathogenic isolate or strain shall be taken to be synonymous with the term “clinically-significant” isolate or strain.
- an "infection" may be a hospital-acquired infection or an infection acquired in a non-hospital environment.
- a hospital-acquired pathogenic Staphylococcus aureus may be transmitted from a hospital environment to the wider community and further, that it is also possible for an infection acquired outside a hospital environment may be introduced into such an environment by a carrier of the pathogen.
- a host may acquire a pathogenic S. aureus in a hospital environment and following or during treatment of the disease state, sufficient viable pathogenic bacteria remain in the host for their transfer to another host in a different environment to occur.
- the present invention is not limited by the environment in which an infection by a pathogenic S. aureus has been acquired.
- the term "commensal isolate” or “non-pathogenic isolate” or similar term shall be taken to refer to any strain of Staphylococcus aureus which, although it may be pathogenic under appropriate conditions, is in the situation at hand, harmlessly associated with a host organism, tissue or cell and does not induce a hospital-acquired infection therein. Most commonly, commensal isolates of S. aureus are present in healthy individuals. Such isolates tend to be, but are not always, sensitive to more than two antibiotics selected from the list comprising gentamycin, penicillin, chloramphenicol, tetracycline, methicillin, erythromycin and kanamycin.
- hospital-acquired infection shall be taken to refer to an infection which is caused by a virulent Staphylococcus aureus bacterium or other microorganism such as another bacterium, a virus or mycoplasma, wherein said infection is characterised by a disease state in a host organism or cell attributable to the virulent bacterium or other microorganism and wherein said virulent bacterium or other microorganism occurs in a laboratory such as, but not limited to, a pathology, serology, biochemistry or microbiology laboratory or, alternatively, a hospital, dental or medical surgery or other healthcare environment.
- hospital shall be taken to include a veterinary hospital or surgery for the treatment of animals such as livestock animals or domestic animals.
- the frequency of occurrence of the subject nucleic acid molecule in a microorganism is determined by any means known to those skilled in the art.
- the frequency of the nucleic acid molecule is determined by polymerase chain reaction and/or nucleic acid hybridisation analyses.
- a "high frequency" of occurrence of the subject nucleic acid molecule refers to its occurrence, as determined by polymerase chain reaction and hybridisation analyses, in at least 50% of pathogenic strains of Staphylococcus aureus, preferably at least 60% of pathogenic strains, more preferably at least 75% and even more preferably at least 90% of all pathogenic strains of S. aureus.
- the term "present at a low frequency" in the present context shall be taken as meaning that less than 20% of commensal Staphylococcus aureus strains carry the sequence, as determined by polymerase chain reaction and hybridisation analyses. Preferably less than 10% of commensal strains, more preferably less than 5 % and even more preferably less than 2 % of commensal S. aureus strains will carry the nucleic acid molecule of the present invention.
- the present invention is not to be limited by the means used to detect the subject nucleic acid molecule as those skilled in the art will be aware of means other then polymerase chain reaction or hybridisation analyses which may be employed for such detection.
- nucleotide sequence shall be taken to refer to an isolated nucleic acid molecule which is substantially the same as the nucleic acid molecule of the present invention or its complementary nucleotide sequence, notwithstanding the occurrence within said sequence, of one or more nucleotide substitutions, insertions, deletions, or rearrangements.
- nucleotide sequence set forth herein shall be taken to refer to an isolated nucleic acid molecule which is substantially the same as a nucleic acid molecule of the present invention or its complementary nucleotide sequence, notwithstanding the occurrence of any non-nucleotide constituents not normally present in said isolated nucleic acid molecule, for example carbohydrates, radiochemicals including radionucleotides, reporter molecules such as, but not limited to DIG, alkaline phosphatase or horseradish peroxidase, amongst others.
- nucleotide sequence set forth herein shall be taken to refer to any isolated nucleic acid molecule which contains significant sequence similarity to said sequence or a part thereof.
- the nucleotide sequence of the present invention may be subjected to mutagenesis to produce single or multiple nucleotide substitutions, deletions and/or insertions.
- Nucleotide insertional derivatives of the nucleotide sequence of the present invention include 5 ' and 3 ' terminal fusions as well as intra-sequence insertions of single or multiple nucleotides or nucleotide analogues.
- Insertional nucleotide sequence variants are those in which one or more nucleotides or nucleotide analogues are introduced into a predetermined site in the nucleotide sequence of said sequence, although random insertion is also possible with suitable screening of the resulting product being performed.
- Deletional variants are characterised by the removal of one or more nucleotides from the nucleotide sequence.
- Substitutional nucleotide variants are those in which at least one nucleotide in the sequence has been removed and a different nucleotide or nucleotide analogue inserted in its place.
- the genetic sequence is particularly useful for the pu ⁇ ose of distinguishing the clinical Staphylococcus aureus strain 8325-4 from other commensal or non-pathogenic strains of bacteria, in particular other strains of S. aureus which do not possess the subject genetic sequence, in particular the sequence set forth in SEQ ID NO: 1 or a homologue, analogue or derivative thereof.
- an alternative embodiment of the invention provides an isolated nucleic acid molecule which is indicative of infection of a host organism, tissue or cell or medical implement by a pathogenic Staphylococcus aureus strain wherein said isolated nucleic acid molecule is :
- (ii) comprises at least one copy of the nucleotide sequence motif: CGATAGCGTA ACA AA ATATGGACCTGTAA AAGGAGACTCG or a complementary sequence or a homologue, analogue or derivative thereof.
- the repeated nucleotide sequence motif is repeated at least two times and more preferably still, at least four times and still more preferably at least six times in the nucleic acid molecule of the invention.
- the present invention provides an isolated nucleic acid molecule which is indicative of infection of a host organism, tissue or cell or medical implement by a pathogenic Staphylococcus aureus strain wherein said isolated nucleic acid molecule is :
- (iii) comprises a sequence of nucleotides or is complementary to a sequence of nucleotides which is at least 40% identical to the sequence set forth in SEQ ID NO:
- the host organism, tissue or cell may be any eukaryotic mammalian cell which is a usual host of a pathogenic strain of Staphylococcus aureus including but not limited to human, domestic animal or livestock animal cells.
- the present invention is particularly directed to cells in vivo, but may also extend to the use of the subject nucleic acid molecule as an indicator of infection of isolated cells, such as cultured cells, by a pathogenic strain of S. aureus.
- Particularly preferred cells according to the present invention are cells associated with a wound site, such as a burn, surgical wound, cut or abrasion, being an accidental or intentional wound, blood cell, bodily fluid such as sputum, lung fluid, urine or vaginal exudate, faeces, epidermal cell, bone or joint cell or food cell, the only requirement being that said cell is capable of being infected by a pathogenic Staphylococcus aureus.
- a “medical implement” may be any implement used in a hospital as hereinbefore defined which is likely to come into contact with a pathogenic Staphylococcus aureus bacterium, such as a surgical catheter, surgical swab, gauze, hospital linen or other such implements and at least capable of maintaining a pathogenic S. aureus cell in a form such that it is capable of subsequently infecting a host organism, tissue or cell as hereinbefore defined.
- a pathogenic Staphylococcus aureus bacterium such as a surgical catheter, surgical swab, gauze, hospital linen or other such implements and at least capable of maintaining a pathogenic S. aureus cell in a form such that it is capable of subsequently infecting a host organism, tissue or cell as hereinbefore defined.
- the term "indicative of infection of a host organism, tissue or cell by a pathogenic Staphylococcus aureus” means that the presence of the nucleic acid molecule in an 5. aureus isolate correlates with the presence of a pathogenic isolate in said cell as the causative agent of infection or disease.
- An isolate bearing the nucleic acid molecule is either pathogenic or is sufficiently related to pathogenic strains to be likely to be pathogenic and may be a member of the same clonal group.
- the nucleic acid molecule could also be a marker of pathogenicity in species other than S. aureus.
- the present invention provides an isolated nucleic acid molecule which is capable of hybridising under at least low stringency conditions to at least 20 contiguous nucleotides contained within the nucleotide sequence set forth in SEQ ID NO: 1 or a complementary strand, homologue, analogue or derivative thereof.
- a low stringency is defined herein as being a hybridisation and/or a wash carried out in 6xSSC buffer, 0.1 % (w/v) SDS at 28°C.
- the stringency is increased by reducing the concentration of SSC buffer, and/or increasing the concentration of SDS and/or increasing the temperature of the hybridisation and/or wash.
- Conditions for hybridisations and washes are well understood by one normally skilled in the art.
- the present invention provides an isolated nucleic acid molecule which is capable of hybridising under at least low stringency conditions to at least 20 contiguous nucleotides contained within the nucleotide sequence set forth in SEQ ID NO: 1 or a complementary strand, homologue, analogue or derivative thereof wherein said nucleic acid molecule is obtained from a Staphylococcus aureus and is present at high frequency in clinically-significant isolates of S. aureus.
- nucleic acid molecule of the invention is either not present or present at a low frequency in commensal isolates of Staphylococcus aureus.
- the nucleic acid molecule further comprises the sequence of nucleotides set forth in SEQ ID NO: 1 or a homologue, analogue or derivative thereof.
- the present invention provides an isolated nucleic acid molecule which encodes or is complementary to a nucleic acid molecule which encodes at least one surface protein or surface-like protein of a pathogenic Staphylococcus aureus strain.
- the isolated nucleic acid molecule of the invention encodes a sequence of amino acids substantially as set forth in any one of SEQ ID NO: 2 or SEQ ID NO: 3 or is at least 40% identical thereto.
- polypeptide 2 and 3 correspond to polypeptides encoded, respectively, by nucleotide residues 189 to 2650 and 2880 to 3455 of the nucleotide sequence set forth in SEQ ID NO: 1.
- the polypeptides are specific to a pathogenic strain of Staphylococcus aureus or at least are present at a high frequency in a pathogenic strain of S. aureus, but only at a low frequency in commensal strains of S. aureus.
- the polypeptide products may be used as markers for identifying a pathogenic strain of S. aureus in a host organism, tissue or cell.
- surface protein or surface-like protein shall be taken to refer to any polypeptide or protein species or a fragment thereof, including a synthetic, recombinant or naturally-occurring polypeptide or protein which is comprised of a sufficient proportion of hydrophilic amino acids such that it may be predicted from its hydrophilic index to be found on the surface of a cell, rather than within the membrane of a cell.
- the present invention extends to any nucleic acid molecule which encodes a fragment of a surface protein or surface-like protein as defined herein, although said fragment is derived from a region of the surface protein or surface-like protein which is found associated with a membrane system or functions as an anchor thereto.
- the nucleic acid molecule according to any of the foregoing embodiments is in a biologically pure form.
- the purity of the nucleic acid molecule is represented by at least 40% nucleic acid molecule, preferably at least 60% nucleic acid molecule, more preferably at least 75 % nucleic acid molecule, even more preferably at least
- nucleic acid molecule 20 85 % nucleic acid molecule and still more preferably at least 90% nucleic acid molecule relative to other nucleic acids and non-nucleic acid material as determined by nucleotide sequence, homology, activity or any other convenient means.
- the genetic sequences of the present invention are particularly useful as genetic probes 25 to identify and/or isolate similar genes or genetic sequences from other pathogenic strains of Staphylococcus aureus.
- a second aspect of the invention contemplates a method of identifying a first nucleic acid molecule from Staphylococcus aureus which is indicative of a pathogenic
- S. aureus strain said method comprising contacting genomic DNA, mRNA, cDNA derived from said S. aureus or a part or fragment thereof, or a source thereof, with a hybridisation effective amount of a second nucleic acid molecule which comprises the nucleotide sequences set forth in SEQ ID NO: 1 or its complementary nucleotide sequence or a part, homologue, analogue or derivative thereof, and then detecting said hybridisation.
- the first nucleic acid molecule may be in a recombinant form, in a virus particle, bacteriophage particle, yeast cell, animal cell, plant cell or any biological sample or medical implement containing a S. aureus cell, in particular a pathogenic S. aureus.
- the first nucleic acid molecule originates from a pathogenic strain of Staphylococcus aureus and/or hybrids or derivatives and/or ancestral progenitors of same.
- the first nucleic acid molecule may be bound to a support matrix, for example nylon, nitrocellulose, polyacrylamide, agarose, amongst others.
- the second genetic sequence is detectably labelled with a reporter molecule capable of giving an identifiable signal (e.g. a radioisotope such as 32 P or 35 S or a biotintylated molecule).
- a reporter molecule capable of giving an identifiable signal (e.g. a radioisotope such as 32 P or 35 S or a biotintylated molecule).
- detectably labelled means that the nucleic acid molecule is labelled with a label or reporter such that the resultant hybrid itself is directly detectable.
- the nucleic acid molecule may be indirectly labelled. These methods are well known to those skilled in the art, and include radiolabeling, and labeled antibody binding. Detection can be achieved by directly labeling the probe with a ligand as, for example, biotin which specifically binds to the protein streptavidin, and the ligand can be a carrier for a chemiluminescent reaction component, as for example streptavidin linked covalently to alkaline phosphatase or horseradish peroxidase. All of these methods are well-known to one of ordinary skill in the art, and render the nucleic acid molecule detectably labeled.
- Radioactive isotopes such as 32 P
- phosphate groups of the phosphate-sugar backbone of the probe molecule Those of ordinary skill in the art will appreciate that labelling with other radioactive labels such as 3 H, or 135 I is also possible.
- detection is accomplished by exposure to X-ray sensitive photographic film or phosphor imager. Subsequent development of the film will enable one to visually detect the presence or absence of hybridisation.
- a method of identifying a first nucleic acid molecule from Staphylococcus aureus which is indicative of a pathogenic S. aureus strain comprising contacting genomic DNA, mRNA, cDNA derived from said S.
- aureus or a part or fragment thereof, or a source thereof with a hybridisation effective amount of a second nucleic acid molecule which comprises the nucleotide sequences set forth in SEQ ID NO: 1 or its complementary nucleotide sequence or a part, homologue, analogue or derivative thereof, and then detecting said hybridisation, wherein said genetic sequence further comprises a sequence of nucleotides substantially as set forth in any one of SEQ ID Nos: 4, 5, 6, 7, 8, 9 or 10 or is at least 40% identical thereto.
- An alternative method contemplated in the present invention involves hybridising under at least low stringency condition, one or more nucleic acid primer molecules of at least
- the template molecule is herein defined as a genetic sequence which is at least 40% identical at the nucleotide sequence level to SEQ ID NO: l or to its complementary nucleotide sequences.
- the polymerase chain reaction a technique that is well known to those skilled in the art.
- the nucleic acid primer molecule or molecule effective in hybridisation is contained in an aqueous mixture of other nucleic acid primer molecules. More preferably, the nucleic acid primer molecule is in a substantially pure form.
- the nucleic acid primer molecule is any nucleotide sequence of at least 10 contiguous nucleotides in length derived from, or contained within the nucleotide sequence as set forth in SEQ ID NO: 1.
- the nucleic acid primer molecule comprises at least 20 contiguous nucleotides in length, even more preferably at least 30 contiguous nucleotides in length and still more preferably at least 40 contiguous nucleotides in length derivable from SEQ ID NO: 1 or its complementary nucleotides substantially the same as any one or more of SEQ ID Nos: 4, 5, 6, 7, 8, 9 or 10 or its complementary nucleotide sequence or a homologue, analogue or derivative thereof.
- the template molecule may be in a recombinant form, in a virus particle, bacteriophage particle, bacterial cell, yeast cell, animal cell, plant cell or any biological sample or medical implement which comprises a S. aureus cell.
- the nucleic acid template molecule originates from a pathogenic strain of Staphylococcus aureus and/or hybrids or derivatives and/or ancestral progenitors of same.
- the nucleic acid template molecule comprises a sequence of at least 30 contiguous nucleotides in length derived from or contained within the sequence set forth in any one of SEQ ID Nos: l, 4,5,6,7,8,9 or 10 or a complementary sequence or a homologue, analogue or derivative thereof.
- the present invention provides a method of determining whether a Staphylococcus strain is pathogenic, said method comprising contacting a biological sample containing nucleic acid from a Staphylococcus strain with a nucleic acid probe comprising at least 10 contiguous nucleotides derived from SEQ ID NO: l or its complement or a homologue, analogue or derivative thereof under at least low stringency hybridisation conditions and for a time sufficient to allow for hybridisation between the nucleic acid in the sample and the probe to occur and then detecting said hybridisation.
- said nucleic acid probe further comprises one or more of the sequences set forth in SEQ ID Nos; 4-10 or a homologue, analogue or derivative thereof.
- hybridisation between the probe and the nucleic acid molecule in the sample is most likely to occur when the sample contains a pathogenic Staphylococcus aureus strain.
- Staphylococcus refers to the species comprising that genus.
- the species used in the method is Staphylococcus aureus, but the method could be extendible to other Staphylococcus species which harbour the genetic sequence where the genetic sequence is a marker of pathogenicity.
- the nucleic acid probe may be RNA or DNA, including a synthetic oligonucleotide molecule, plasmid DNA molecule or contained in any other nucleic acid molecule. Furthermore, the probe may be single-stranded or double-stranded.
- the probe may be modified by the attachment of any reporter molecule to facilitate the detection of hybridisation.
- the probe is detectably labelled using a reporter molecule comprising a radioactive isotope such as 32 P or 35 S.
- the sample may be any biological sample which contains a Staphylococcus aureus cell, including, but not limited to a biological sample derived from a wound site, blood cell, bodily fluid such as urine, faeces or vaginal exudate, epidermal cell, bone or joint cell or food cell, or a medical implement as hereinbefore defined which is contaminated with a Staphylococcus aureus cell.
- sample preparation typically involves lysis of cells contained in the sample, in particular lysing the Staphylococcus cells.
- Sample preparation may further include gel electrophoresis of the contents and then transfer to a membrane or direct dot blot, followed by probing with a suitably labelled probe, under at least low stringency conditions.
- the sample is limited or the level of S. aureus contamination of the sample or the S. aureus cell count in the sample is low, it may be possible to amplify the S. aureus DNA as hereinbefore described, prior to electrophoresis of the sample and subsequent nucleic acid hybridisation.
- a suitably prepared sample comprises representative nucleic acid sequences for the species of Staphylococcus contained therein. This means that most and preferably all of the complement of Staphylococcus genetic sequences in the form of RNA, DNA or protein are present in the prepared sample, such that the detection means used will be able to detect the relevant sequences when present in the intact bacterium.
- a further aspect of the present invention is directed to a genetic construct comprising an isolated nucleic acid molecule as described herein.
- the gene sequence is related to or a functional derivative, part fragment, homologue, or analogue of the nucleotide sequence defined by any one or more of SEQ ID NO: 1 or SEQ ID NOs: 4-10 inclusive.
- the present invention extends to genetic constructs designed to facilitate the expression of a nucleic acid molecule as described herein, in which case the genetic construct will comprise, in addition to the subject nucleic acid molecule, a promoter and optional other regulatory sequences that modulate expression of the nucleic acid molecule.
- the promoter may be any promoter capable of expression in a bacterial or mammalian cell.
- promoter sequence used in the expression vector will also vary depending upon the level of expression required and whether expression is intended to be constitutive or regulated.
- eukaryotic cells contemplated herein include mammalian, yeast, insect or plant cells and examples of prokaryotes include Escherichia coli, Salmonella sp., Bacillus sp. and Pseudomonas sp.
- Typical promoters suitable for expression in bacterial cells such as E. coli include, but are not limited to, tac promoter, the lacz promoter, or the phage lambda ⁇ L or ⁇ R promoters.
- the subject nucleic acid molecule may be genomic DNA or cDNA and may correspond in sequence exactly with the nucleotide sequence as set forth in SEQ ID NO: 1 or SEQ ID NOs: 4, 5, 6, 7, 8, 9 or 10, or it may contain one or more nucleotide substitutions, additions and/or deletions, either dispersed throughout, or clustered.
- Yet another aspect of the present invention provides a recombinant gene product which comprises at least one surface protein or surface-like protein as hereinbefore defined of a pathogenic strain of Staphylococcus aureus.
- the gene product has a sequence that is identical to, or contained within the amino acid sequence set forth in SEQ ID NO: 2, or SEQ ID NO: 3 or a homologue, analogue or derivative thereof which is at least 40% identical thereto.
- the present invention also extends to a synthetic peptide comprising any part of the amino acid sequence set forth in SEQ ID NO: 2 and/or SEQ ID NO: 4, or a derivative having at least 40% similarity to all or a part thereof.
- the peptide is in biologically pure form.
- the purity of the peptide is represented by at least 40% peptide, preferably at least 60% peptide, more preferably at least 75 % peptide, even more preferably at least 85 % peptide and still more preferably at least 90% peptide relative to other peptides, proteinaceous and non- proteinaceous material as determined by amino acid sequence, homology, activity or any other convenient means.
- Derivatives of the polypeptides of the invention include single or multiple amino acid substitutions, deletions and/or additions to the molecule. Conveniently, these are prepared by first making single or multiple nucleotide substitutions, deletions and/or additions to the nucleic acid molecule encoding the polypeptide. Alternatively, once the amino acid sequence is known, amino acids can be chemically added by established techniques and in any sequence required to give the desired mutant. All such derivatives are encompassed by the present invention.
- Amino acid insertional derivatives of the polypeptides of the present invention include amino and/or carboxyl terminal fusions as well as intra-sequence insertions of single or multiple amino acids.
- Insertional amino acid sequence variants are those in which one or more amino acid residues are introduced into a predetermined site in the protein although random insertion is also possible with suitable screening of the resulting product.
- Deletional variants are characterised by the removal of one or more amino acids from the sequence.
- Substitutional amino acid variants are those in which at least one residue in the sequence has been removed and a different residue inserted in its place. Typical substitutions are those made in accordance with Table 1.
- amino acids are generally replaced by other amino acids having like properties, such as hydrophobicity, hydrophilicity, electronegativity, bulky side chains and the like.
- Amino acid substitutions are typically of single residues.
- Amino acid insertions will usually be in the order of about 1-10 amino acid residues and deletions will range from about 1-20 residues.
- deletions or insertions are made in adjacent pairs, i.e. a deletion of two residues and a corresponding insertion of two residues. TABLE 1 Suitable residues for amino acid substitutions
- amino acid variants referred to above may be readily made using synthetic peptide techniques well known in the art, such as solid phase peptide synthesis and the like, or by recombinant DNA manipulations. Techniques for making substitution mutations at predetermined sites in DNA having known or partially known sequence are well known and include, for example, M13 mutagenesis. The manipulation of DNA sequence to produce variant proteins which manifest as substitutional, insertional or deletional variants are conveniently described, for example, in Sambrook et al (1989).
- recombinant or synthetic mutants and derivatives of a polypeptide include single or multiple substitutions, deletions and/or additions of any molecule associated therewith such as carbohydrates, lipids and/or proteins or polypeptides.
- the isolated recombinant polypeptides set forth in SEQ ID Nos: 2 and 3 are useful as polypeptide components in vaccine preparations which, when administered to a human or other animal capable of being infected by a pathogenic Staphylococcus aureus, confer immunity or resistance, or at least improve resistance of a host organism, tissue or cell to said pathogenic bacterium.
- polypeptide of the invention is useful as a marker for the identification of a pathogenic strain or Staphylococcus aureus.
- the detection of the subject polypeptide by any means known in the art, for example SDS/polyacrylamide gel electrophoresis, immunoassay, enzyme assay or other means may be used.
- an immunoassay it is first necessary to produce an immunologically interactive molecule to the polypeptide of the invention.
- polypeptides of the invention are also useful in the production of immunologically interactive molecules, such as antibodies, or functional derivatives thereof.
- a further aspect of the invention further contemplates an antibody that binds to a surface protein or surface-like protein of a pathogenic Staphylococcus aureus as hereinbefore defined or a homologue, analogue or derivative thereof.
- said antibody is further capable of binding to a sequence of amino acids that is identical to, or contained within the sequence set forth in SEQ LD NO: 2, or SEQ ID NO: 3 or a homologue, analogue or derivative thereof which is at least 40% identical thereto.
- an antibody as contemplated herein includes any antibody which is capable of binding to any region of a recombinant gene product derived from a Staphylococcus aureus, wherein said gene product is present at a high frequency in pathogemc strains of S. aureus and at a low frequency in commensal strains of S. aureus or is a surface protein or surface-like protein as hereinbefore defined.
- the antibody is capable of binding to a contiguous or non-contiguous region of at least 5 amino acid residues derived from SEQ ID NO: 2 or SEQ ID NO: 3.
- the present invention extends to recombinant and synthetic antibodies and to antibody hybrids.
- a "synthetic antibody” is considered herein to include fragments and hybrids of antibodies.
- the antibodies may be monoclonal or polyclonal and may be selected from naturally occurring antibodies to a gene product or may be specifically raised to a recombinant S. aureus gene product. In the case of me latter, the gene product may first need to be associated with a carrier molecule.
- the present invention contemplates whole antibodies, antibody fragments, poly functional antibody reagents, monoclonal antibodies, single-chain antigen-binding molecules, or in general any substance comprising one or more specific binding sites from an anti-hybrid antibody. When in the form of whole antibody, it can belong to any of the classes and subclasses of known immunoglobulins, e.g., IgG, IgM, and so forth.
- any fragment of any such antibody which retains specific binding affinity for the hybridized probe can also be employed, for instance, for fragments of IgG conventionally known as Fab, F(ab'), and F(a') 2 -
- fragments of IgG conventionally known as Fab, F(ab'), and F(a') 2 - fragments of IgG conventionally known as Fab, F(ab'), and F(a') 2 -
- aggregates, polymers, derivatives and conjugates of immunoglobulins or their fragments can be used where appropriate.
- the immunoglobulin source for the antibody reagent can be obtained in any available manner such as conventional antiserum, monoclonal antibody techniques, and recombinant 5 genetic engineering of single-chain antigen-binding molecules.
- Antiserum can be obtained by well-established techniques involving immunization of an animal, such as a mouse, rabbit, guinea pig, sheep or goat, with an appropriate immunogen.
- Antiserum can also be obtained from a human or animal patient which has been infected by S. aureus.
- the immunoglobulins can also be obtained by somatic cell hybridisation techniques, such resulting in what are 10 commonly referred to as monoclonal antibodies, also involving the use of an appropriate immunogen.
- Single-chain antigens are recombinantly engineered by insertion of a DNA segment coding for a linker polypeptide into a plasmid such that the linker will be expressed linking the two antigen-binding variable domains.
- Both polyclonal and monoclonal antibodies are obtainable by immunisation with a recombinant gene product, native protein or extract derived from a pathogenic S. aureus and either type is utilisable for immunoassay s.
- the methods of obtaining both types of sera are well known in the art.
- Polyclonal sera are less preferred but are relatively easily prepared by injection of a suitable laboratory animal such as a mouse, rabbit, guinea pig, sheep or goat
- the use of monoclonal antibodies in an immunoassay is particularly preferred because 25 of the ability to produce them in large quantities and the homogeneity of the product.
- the preparation of hybridoma cell lines for monoclonal antibody production derived by fusing an immortal cell line and lymphocytes sensitised against the immunogenic preparation can be done by techniques which are well known to those who are skilled in the art (see, for example, Douillard and Hoffman, 1981; Kohler and Milstein, 1975; Kohler and Milstein, 30 1976).
- the antibodies and/or the recombinant S. aureus gene products of the present invention are particularly useful for the immunological screening of biological samples derived from a host organism, tissue or cell infected with a pathogemc strain of S. aureus to detect the presence of said pathogen therein.
- specific antibodies are used to screen for pathogenic Staphylococcus aureus isolates in a host organism, tissue or cell.
- Techniques for the assays contemplated herein are known in the art and include, for example, sandwich assays and ELISA.
- first and second antibodies may be used in detection assays or a first antibody may be used with a commercially available anti-immunoglobulin antibody.
- the detection of a pathogenic Staphylococcus aureus strain in a host organism, tissue or cell may be accomplished in a number of ways such as by Western blotting and ELISA procedures.
- a wide range of immunoassay techniques are available as can be seen by reference to US Patent Nos. 4,016,043, 4, 424,279 and 4,018,653. These, of course, include both single-site and two-site or "sandwich" assays of the non-competitive types, as well as in the traditional competitive binding assays. These assays also include direct binding of a labelled antibody to a target.
- Sandwich assays are among the most useful and commonly used assays and are favoured for use in the present invention.
- an unlabelled antibody is immobilised on a solid substrate and the sample to be tested brought into contact with the bound molecule.
- a second antibody specific to the antigen labelled with a reporter molecule capable of producing a detectable signal is then added and incubated, allowing time sufficient for the formation of another complex of antibody-antigen-labelled antibody. Any unreacted material is washed away, and the presence of the antigen is determined by observation of a signal produced by the reporter molecule.
- the first antibody is raised to a recombinant gene product encoded specifically by a pathogenic strain of Staphylococcus aureus and the antigen is derived from a pathogenic strain of S. aureus, preferably in a host organism, tissue or cell, host organism, tissue or cell extract or biological sample suspected of being contaminated with said strain.
- results may either be qualitative, by simple observation of the visible signal, or may be quantitated by comparing with a control sample containing known amounts of hapten.
- Variations on the forward assay include a simultaneous assay, in which both sample and labelled antibody are added simultaneously to the bound antibody. These techniques are well known to those skilled in the art, including any minor variations as will be readily apparent.
- the sample is one which might contain a pathogemc S. aureus or a gene product thereof and include crude or purified protein extracts.
- S. aureus gene product is either covalently or passively bound to a solid surface.
- the solid surface is typically glass or a polymer, the most commonly used polymers being cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.
- the solid supports may be in the form of tubes, beads, discs of microplates, or any other surface suitable for conducting an immunoassay.
- the binding processes are well-known in the art and generally consist of cross-linking, covalent binding or physically adso ⁇ tion, the polymer-antibody complex is washed in preparation for the test sample. An aliquot of the sample to be tested is then added to the solid phase complex and incubated for a period of time sufficient (e.g.
- reaction locus is washed and dried and incubated with a second antibody specific for a portion of the first antibody.
- the second antibody is linked to a reporter molecule which is used to indicate the binding of the second antibody to the hapten.
- An alternative method involves immobilising the target molecules in the biological sample and then exposing the immobilised target to specific antibody which may or may not be labelled with a reporter molecule. Depending on the amount of target and the strength of the reporter molecule signal, a bound target may be detected by direct labelling with the antibody. Alternatively, a second labelled antibody, specific to the first antibody is exposed to the target-first antibody complex to form a target-first antibody-second antibody tertiary complex. The complex is detected by the signal emitted by the reporter molecule.
- reporter molecule as used in the present context, is meant a molecule which, by its chemical nature, provides an identifiable signal which allows the detection of antigen- bound antibody. Detection may be either qualitative or quantitative.
- the most commonly used reporter molecules in this type of assay are either enzymes, fluorophores or radionuclide containing molecules (i.e. radioisotopes) and chemiluminescent molecules for example LUMI- PHOS 530 (registered trade mark of LuminGen Inc., Detroit, Michigan, USA) or an antidigoxygenin conjugate.
- an enzyme is conjugated to the second antibody, generally by means of glutaraldehyde or periodate.
- glutaraldehyde or periodate As will be readily recognised, however, a wide variety of different conjugation techniques exist, which are readily available to the skilled artisan.
- Commonly used enzymes include horseradish peroxidase, glucose oxidase, beta-galactosidase and alkaline phosphatase, amongst others.
- the substrates to be used with the specific enzymes are generally chosen for the production, upon hydrolysis by the corresponding enzyme, of a detectable colour change. Examples of suitable enzymes include alkaline phosphatase and peroxidase.
- the enzyme-labelled antibody is added to the first antibody-hapten complex, allowed to bind, and then the excess reagent is washed away. A solution containing the appropriate substrate is then added to the complex of antibody-antigen-antibody. The substrate will react with the enzyme linked to the second antibody, giving a qualitative visual signal, which may be further quantitated, usually spectrophotometrically, to give an indication of the amount of hapten which was present in the sample.
- reporter molecule also extends to use of cell agglutination or inhibition of agglutination such as red blood cells on latex beads, and the like.
- fluorescent compounds such as fluorescein and rhodamine
- fluorescein and rhodamine may be chemically coupled to antibodies without altering their binding capacity.
- the fluorochrome-labelled antibody When activated by illumination with light of a particular wavelength, the fluorochrome-labelled antibody adsorbs the light energy, inducing a state to excitability in the molecule, followed by emission of the light at a characteristic colour visually detectable with a light microscope.
- enzyme immunoassays EIA
- the fluorescent labelled antibody is allowed to bind to the first antibody- hapten complex. After washing off the unbound reagent, the remaining tertiary complex is then exposed to the light of the appropriate wavelength the fluorescence observed indicates the presence of the hapten of interest.
- Immunofluoresence and EIA techniques are both very well established in the art and are particularly preferred for the present method. However, other reporter molecules, such as radioisotope, chemilummescent or bioluminescent molecules, may also be employed
- any enzyme may be coupled to the bound antibodies for pu ⁇ oses of detection, including horseradish peroxidase and glutaraldehyde, and corresponding color-developing reagents applied.
- antidigoxigenin conjugates that would be suggested to one of ordinary skill include the fluoresces anti-digoxigenin-rhodamine, and anti- digoxigenin-fluorescein; and for electron microscopy anti-digoxigenin-(second antibody conjugated to gold).
- chromophoric labels can be detected by sight or by conventional means, such as by a light microscope. Recordation is by conventional color microphotography. Fluorescent or chemilumescent labels emit light that may be detected by sight or by photomultiplier type. Gold-conjugated labeling is used in electron microscopy to detect hybridisation and to image the larger mo ⁇ hological features of the infected cell. Radiolabeled probes may be exposed to X-ray sensitive film and image analysis software such as a densitometer or phosphor imager.
- the invention also extends to an immunologically reactive molecule capable of binding a nucleic acid hybrid molecule, wherein said hybrid comprises a first nucleic acid molecule as hereinbefore defined hybridised to a second nucleic acid molecule present in or derived from a biological sample or medical implement.
- the immunologically interactive molecule When used to detect a hybrid nucleic acid molecule, it will usually be labeled with a reporter molecule as hereinbefore defined.
- the antibody reagent can be detected based on a native property such as its own antigenicity. Further, antibody can be detected by complement fixation or the use of labeled protein A, as well as other techniques known in the art for detecting antibodies.
- the sensitivity of detection may be enhanced by amplifying Staphylococcus genetic sequences using the polymerase chain reaction before hybridising the nucleic acid molecule of the invention or using an immunologically interactive molecule to detect said hybrids.
- the present invention contemplates use of the isolated peptide described above as a vaccine for Staphylococcus, particularly S. aureus.
- a vaccine for Staphylococcus said vaccine comprising an immunogenically effective amount of a peptide or part of said peptide, which is encodable by the 3.5 kb or 40 bp nucleic acid molecules described earlier together with a pharmaceutically acceptable carrier or diluent.
- the peptide or part peptide of the present invention is referred to as the "active ingredient”.
- the vaccine preparation is conveniently referred to below as “the pharmaceutical composition”.
- the active ingredient of the pharmaceutical composition is contemplated to exhibit excellent activity in stimulating, enhancing or otherwise facilitating an immune response in patients when administered in an amount which depends on the particular case. For example, from about 0.5 ⁇ g to about 20 mg of peptide per kilogram of body weight per day may be administered. Dosage procedures may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered in one or more of daily, weekly or monthly or in other suitable time intervals or the dose may be proportionally reduced as indicated by the exigencies of the situation.
- the active compound may be administered by injection in a convenient manner but may be administered via a genetic sequence in a viral or bacterial vector.
- the active compounds may also be administered in dispersions prepared in glycerol, liquid polyethylene glycols, and/or mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
- the pharmaceutical forms suitable for in vivo administration include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
- vaccine preparation may be delivered by oral means.
- the vaccine may be delivered as a coating on a gold or tungsten particle or other particle via a biolistic means, to a target cell or tissue.
- the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
- the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thormerosal and the like.
- isotomc agents for example, sugars or sodium chloride.
- Prolonged abso ⁇ tion of the injectable compositions can be brought about by the use in the compositions of agents delaying abso ⁇ tion, for example.
- Sterile injectable solutions are prepared by inco ⁇ orating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by inco ⁇ orating the various sterilized active ingredient(s) into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
- the preferred methods of preparation are vacuum drying and the freeze-drying technique which yield a powder of me active ingredient plus any additional desired ingredient from previously sterile- filtered solution thereof.
- pharmaceutically acceptable carriers and/or diluents include any and all solvents, dispersion media, aqueous solutions, coatings, antibacterial and antifungal agents, isotonic and abso ⁇ tion delaying agents, and the like.
- the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in the composition is contemplated. Supplementary active ingredients can also be inco ⁇ orated into the compositions.
- a further aspect of the present invention contemplates a kit for the rapid and convenient detection of a pathogenic Staphylococcus, in particular a pathogenic S. aureus in a biological sample such as serum, mucus, tissue extract, or biological fluid or in a medical implement as hereinbefore defined.
- the kit is compartmentalized to receive several first containers adapted to contain a polypeptide according to any of the embodiments hereinbefore described and several second containers adapted to contain an antibody which recognises said polypeptide, wherein said antibody is optionally labelled with a reporter molecule capable of producing a detectable signal as hereinbefore described. If the antibody of the second container is not labelled with a reporter molecule, then there are also provided several third containers which contain a second antibody which recognises the first antibody and is conjugated to a reporter molecule. If the reporter molecule is an enzyme, then several fourth containers are provided which contain a substrate molecule for said enzyme to facilitate detection of the enzyme linked to a polypeptide:antibody complex, or to a polypeptide: antibody: antibody complex when a second antibody has been used.
- the reporter molecule used in this kit may also be a radio-isotope, a fluorescent molecule, or bioluminescent molecule, amongst others.
- the first, second, third and fourth containers of said kit may be colour-coded for ease-of use.
- a control reaction is carried out in which the contents of the first container are contacted with the contents of the second container for a time and under conditions sufficient for an antibody: polypeptide complex to form in said first container.
- the sample to be tested is contacted with the contents of the second container for a time and under conditions sufficient for an antibody:polypeptide complex to form in said second container.
- the antibody of the second container provided is not labelled with a reporter molecule, then the complexes produced in said first and second containers are contacted with the antibody of the third container for a time and under conditions sufficient for a tertiary polypeptide:antibody:antibody complex to form.
- polypeptide: antibody complex or polypeptide:antibody:antibody complex is then subjected to a detecting means as hereinbefore described.
- the control reaction carried out in said first container should always provide a positive result upon which to compare the results obtained in said second container which contains the test sample.
- the kit of the present invention is also useful for the rapid and convenient assay of infection by a pathogenic Staphylococcus bacterium, in particular S. aureus in an human or other animal, in which case the sample being tested is derived from a human or other animal suspected of being infected with said bacterium.
- the present invention further contemplates a kit for the rapid detection of a pathogenic Staphylococcus, in particular a pathogenic S. aureus in a biological sample, said kit being compartmentalized to contain in a first compartment, one or more nucleic acid molecules which encode, or are complementary to a nucleic acid molecule as hereinbefore defined.
- the first compartment is adapted to contain one or more nucleic acid molecules which are at least 40% identical to the nucleotide sequence set forth in SEQ LD Nos:l, 4,5,6,7,8,9 or 10 or its complement or a derivative, homologue or analogue thereof.
- Figure 1 is a photographic representation showing the detection of recombinant plasmid DNA with a nucleic acid molecule which is specific for the pathogemc Staphylococcus aureus strain ISP8. Plasmid recombinants (lanes 2-5) were hybridised with radiolabelled pooled total DNA obtained from 30 individual commensal isolates (top panel) and total ISP8 DNA (lower panel). Lane 1 contains pTZ19U DNA. Hybridisation signals in lanes other than lane 4 are due to non-specific binding of the DNA probes to plasmid DNA.
- Figure 2 is a photographic representation showing the detection of pathogen-specific nucleic acid sequences in pathogenic (top panel) and commensal (lower panel) isolates of Staphylococcus aureus.
- Total genomic DNA was obtained from isolates and digested with H dIII and then hybridisaed with the fragment set forth in SEQ ID NO: 4. Variation in signal intensity is most likely due to differences in DNA loading per lane.
- Clinical isolates not showing a detectable signal are antibiotic-sensitive and non-clonal.
- Commensal isolates showing a detectable signal are antibiotic-sensitive and clonal. Sizes of DNA fragments are indicated on the right-hand side of the figure.
- Figure 3 is a photographic representation showing the amplification products generated from various Staphylococcus aureus isolates using the primers WAS 3' and WAS 2R.
- Lane 1 shows a pTZ19U marker
- lane 2 contains no added DNA
- Lane 3 contains the amplification product obtained using S. aureus ISP8 genomic DNA as a template
- Lanes 4-13 inclusive contain the amplification products obtained using other isolates (lanes 4-6 and 8-11 are from clonal isolates while lanes 7, 12 and 13 are from non-clonal isolates).
- Figure 4 is a schematic representation showing the open reading frame 1 (ORF1) and summarising the structure of the repeated units which comprise the 40bp nucleotide repeat sequence revealed by nucleotide sequence analysis.
- ORF1 open reading frame 1
- the numbers below the boxes indicate nucleotide positions within ORF1. Numbers within the boxes indicate the number of the repeat unit.
- Figure 5 is a schematic representation showing the analysis of the amino acid sequences encoded by ORF1 (SEQ ID NO:2).
- the predicted hydrophilicity profile was determined according to Kyte and Doolittle (1982) using a window of seven amino acid residues.
- the vertical axis indicates the relative hydrophilicity (positive values) or relative hydrophobicity (negative values).
- the horizontal axis denoted the amino acid residue position.
- Surface probability, antigenic index and secondary structure predictions were determined using the Mac Vector 3.5 (IBI) computer software which utilises a combination of algorithms. Values greater than 0.5 on the vertical axis indicate amino acids exposed to the surface of the membrane. Values greater than 0.0 indicate surface peaks that might comprise highly antigenic sites.
- CF indicates Chou and Fasman (1978) predictions, while RG indicates Robson-Garnier (Gamier et al, 1978) predictions and CfRg indicates a combination of the two predictive methods for determining the secondary structure of proteins.
- Hlx indicates helix; Sht indicates beta sheet and Trn indicates a beta-turn
- Figure 6 is a schematic representation showing the analysis of the amino acid sequences encoded by ORF2 (SEQ ID NO:3).
- the predicted hydrophilicity profile was determined according to Kyte and Doolittle (1982) using a window of seven amino acid residues.
- the vertical axis indicates the relative hydrophilicity (positive values) or relative hydrophobicity (negative values).
- the horizontal axis denoted the amino acid residue position.
- Surface probability, antigenic index and secondary structure predictions were determined using the Mac Vector 3.5 (IBI) computer software which utilises a combination of algorithms. Values greater than 0.5 on the vertical axis indicate amino acids exposed to the surface of the membrane. Values greater than 0.0 indicate surface peaks that might comprise highly antigenic sites.
- CF indicates Chou and Fasman (1978) predictions, while RG indicates Robson-Garnier (Garnier et al, 1978) predictions and CfRg indicates a combination of the two predictive methods for determining the secondary structure of proteins.
- Hlx indicates helix; Sht indicates beta sheet and Trn indicates a beta-turn.
- Staphylococcus aureus strain 8325-4 (ISP8, Patel et al., 1989) was kindly provided by Dr Peter Pattee, Iowa State University.
- NCTC 8325 (parent of ISP8), though originally isolated in England in the 1950s, appears to be similar, as determined by RFLP analysis, to recent types of MRSAs and to some recent MSSAs isolated in Australia.
- ISP8 was identified as belonging to the clonal population, and was selected as representative of the clinically significant clonal isolates, which include MSSAs and MRSAs closely related to ISP8.
- Strain ANS46 is a methicillin-multiresistant Staphylococcus aureus (MRSA) extensively studied in this and other laboratories, and is representative of a group (referred to as type 46) which was dominant in major hospitals in the eastern Australian states during 1982 and 1986 (Heneine & Stewart, 1986; Gillespie et al, 1987; Matthews et al, 1987; Skinner et al, 1988; Inglis et al, 1991; Dubin et al, 1992).
- the second Australian MRSA strain lb is representative of a group referred to as type I (subtype b), a clonal group prevalent in hospitals in Canberra, Australia, during the period 1989-1990 (El-Adhami et al, 1991).
- Strains SK565 and SK597 are from a collection of MRSA isolates kindly provided by Dr RA Skurray, Sydney University, Sydney, Australia. These two strains were isolated during the period 1981-1982; the former was isolated from Royal Brisbane Hospital, Brisbane, and the latter was isolated from Royal Prince Alfred Hospital, Sydney, Australia (Lyon et al, 1984).
- Staphylococcus aureus isolates were collected by nasal swabbing from a random selection of healthy individuals (university students with no recent history of staphylococcal disease) in Canberra during 1990; these express resistance to not more than two antibiotics. Isolates were identified as S. aureus isolates by their ability to grow and ferment mannitol on 5% (w/v) NaCl nutrient agar (Oxoid), and by a positive coagulase test. Antibiotic susceptibilities were tested by the BBL Sensi-Disc System (Bection Dickinson).
- the cell walls were digested in the presence of lysostaphin (50 ⁇ g/ml) in a lysis solution (1M NaCl, lOOmM EDTA, 6mM Tris Cl pH 7.6, 0.5 % Sarkosyl, 0.2% deoxycholate, 20mg/ml DNAase-free RNAase, 1 mg/ml lysozyme) at 37°C for 4 h.
- the lysis solution was discarded and the agarose plugs were incubated in ESP solution (0.5M sodium EDTA pH 9.3, 1 % Sarkosyl, 0.5 mg/ml proteinase K) at 50°C for 24h.
- the DNA plugs were then washed and digested with endonucleases as described by Inglis et al. (1990).
- TES TrisCl pH 8.0, 50 mM NaCL, 5m MEDTA
- 2.5M NaCl and lysostaphin at 30 ⁇ g/ml.
- the lysed suspension was then extracted with Tris-equilibrated phenol (pH 8.0), and the DNA was precipitated with ethanol, dried and dissolved in 0.5ml TE buffer (lOmM TrisCl pH 8.0, lmM EDTA) by gentle repeated inversion overnight at 4°C.
- DNAase-free RNAase was then added to 50 ⁇ g/ml and the solution incubated at 37°C for 30 min, and was purified by layering onto 3.8ml of IM NaCl, 20mM TrisCl Ph 8.0 and centrifugation at 58000 ⁇ m for 2h at 20°C (Matthews et al, 1987). The buffer was then drained and the dried DNA pellet was dissolved in TE buffer.
- ISP8 DNA was digested with the endonuclease Taql (Pharmacia), while community
- DNA was denatured and fragmented by mixing with NaOH (final concentration 0.3 M) and heating to 100°C for 10 min. The mix was neutralized with Tris.Cl, pH 7.5 and concentrated HCI (Matthews et al, 1987). Fragmented community DNA was then mixed with Taql restricted ISP8 DNA at a ratio of 200: 1, boiled at 100° C for 10 min, and then allowed to anneal at 65 °C for approx. 18 hr. An aliquot of the annealed DNA mix was mixed with AccI (Pharmacia) restricted, dephosphorylated pTZ19U (BioRad) at a ratio of 10: 1 , in the presence of T4 DNA ligase (Pharmacia).
- the ligated DNA was used to transform electrocompetent E. coli MCI 061.1, and transformants were plated onto ampicillin-containing media (Sambrook et al, 1989). TABLE 2 Antibiotic susceptibility phenotypes for the MRSA, MSSA and COSA isolates.
- t Gm gentamycin
- Pc penicillin
- Cm chloramphenicol
- Tc tetracycline
- Km kanamycin.
- S sensitive, R, resistant, IR, intermediate resistance (the zone of inhibition falls between that determined for standard S and R strains; BBL Sensi- Disc System).
- Plasmids were prepared by the alkaline lysis method (Sambrook et al, 1989), electrophoresed in 1 % agarose in lx TAE electrophoresis buffer under standard electrophoresis conditions (Sambrook et al, 1989), and transferred to Nylon membranes (Hybond N + ; Amersham). Standard cloning and screening methods (Sambrook et al, 1989) were used to clone the full length specific DNA identified in subtractive hybridisation.
- DNA probes were prepared from total chromosomal DNA from ISP8, community isolates (separately), and from plasmids using the Megaprime DNA labelling system (Amersham, a random-printing method; Feinberg and Vogelstein, 1983, 1984). Filters were hybridized in 2x PE, 7% SDS, and 1 % BSA at 70 ⁇ C for 16-18 h, then washed three times (10 min each) in 2x SSC, 0.1 % SDS at room temperature, followed by two 10 min washes in 0.5x SSC, 1 % SDS at 70°C. The filters were the exposed to Fuji X-ray film at -70°C. Results are presented in Figure 1.
- Staphylococcus aureus isolates (El-Adhami and Stewart, in preparation), the method of subtractive hybridisation (Lamar and Palmer, 1984) and cloning was applied to detect and identify the presence of any unique DNA sequences associated with the clinical and clonal populations of S. aureus but not with commensal (community) ones.
- the S. aureus strain NCTC 8325-4 (ISP8, a variant of the standard strain NCTC 8325 isolated from a clinical environment in the 1950s; Pattee, 1993) was used as a representative of the types with greater clinical virulence.
- This strain is related to the recent climcal types identified in major hospitals on the Eastern-Australian coast. It has been extensively mapped, both physically and genetically (Pattee, 1993).
- This strain does not carry any of the repeat sequences, such as IS elements, transposons, plasmids, or bacteriophages identified to date for the staphylococci.
- Unique DNA sequences may be accessible by deletion enrichment, since such sequences can be considered "deleted" from the commensal isolates.
- ISP8 specific-DNA sharing no homology to the community DNA, was free to re- anneal and was subsequently cloned by standard cloning techniques into pTZ19U. Electroporation was used to transform E. coli MC106.1, and transformants were plated onto ampicillin-containing media (Sambrook et al, 1989).
- Recombinant plasmids obtained from subtractive hybrid isolation and ligation, were screened by hybridisation to DNA probes generated from ISP8 total DNA, and from the pooled community isolates total DNA.
- a second round of hybridisation was carried out in which the plasmid with the specific DNA was used as a probe to hybridize to Nylon membranes with Hr ⁇ dlll restricted DNA from twenty climcal isolates, and another twenty community isolates (different from the ones used in the initial subtractive hybridisation process).
- One plasmid carrying ISP8 specific-DNA was recovered which hybridized, under stringent conditions, to an identical size fragment (approx. l lkb of H dIII restricted DNA) in 12/20 clinical isolates and 3/30 community isolates ( Figure 2).
- the positively hybridizing isolates belonged to the genetically closely related types (clones); ie. clones of greater clinical virulence.
- DNA obtained from seven clonal pathogenic isolates of Staphylococcus aureus and three non-pathogenic isolates were screened by using synthetic oligonucleotide primers designated WAS 3' (SEQ ID NO: 6) and WAS 2R (SEQ ID NO: 8)
- the synthetic oligomers were used for PCR amplification of a nucleic acid molecule of approximately 300 bp in length. Standard PCR conditions were used.
- the 300 bp DNA fragment amplified during the PCR reaction was only produced when DNA isolated from clonal pathogenic strains was used as template DNA, indicating that the amplification reaction using these primers provides a successful diagnostic assay for clonal pathogenic S. aureus isolates.
- a genomic library was generated from Dral restricted ISP8 representing fragments within 2-4 kb in size. These fragments were ligated into pBluescript (Stratagene) and used to transform E. coli MC1061.1 cells. The generated library was screened by using synthetic oligomers designed from the sequenced 40 bp insert (primer WAS 3'; SEQ ID NO:6) and from sequence obtained from cycle sequencing genomic DNA described below (primer WAS 2R; SEQ ID NO: 8) utilizing PCR amplification.
- Primers (24 mers in both 5' and 3' directions) were designed from me 40 bp sequence (SEQ ID NO:4) and were used to obtain more sequence information by cycle sequencing. The above oligonucleotides and the following primers were used for sequence extension.
- WAS 3' (SEQ ID NO:6) 5'-CGAGTCTCCTTTTACAGGTCCATA-3'
- WAS 2 SEQ ID NO:7 5'-GCGTCGTTATTGTCTTCTCACCT-3 ⁇
- WAS 2R (SEQ ID NO: 8) 5 '-AGGTGAGAAGACAATAACGACGC-3 ' ,
- WAS 3 (SEQ ID NO: 9) 5'-CAGGAGAGAAAGAGGAAGTTCCAG-3' or
- WAS 3R (SEQ ID NO: 10) 5 '-CTGGAACTTCCTCTTTCTCTCCTG-3 '
- the 3.487 kb DNA fragment was sequenced by generating deletion subclones using the Promega Erase-a-Base system. Methods for deletion, subcloning and sequencing are provided in the Promega Users Guide.
- ORF 1 is 2.475 kb and encodes a protein of 824 amino acids whereas ORF 2 only 576 bp which encodes a protein of 192 amino acids.
- ORFs open reading frames
- IBI Mac Vector 3.5
- ORFl open reading frames
- the coding region of ORFl starts with the initiation codon ATG at nt 179 (another possible start codon is TTG at nucleotide 191), and terminates with the stop codon TGA at nt 3,650.
- RBS ribosome binding site
- ORF2 The second largest ORF (ORF2) identified in the third translational frame starts with a GTG initiation codon at nucleotide 2,880, and terminates with a TAG codon at position 3,456.
- GTG is not a commonly used initiation codon, it has been reported to have this function in the synthesis of several bacterial proteins (Signas et al, 1989).
- the nucleotide base composition for both ORFl and 2 is A and T rich, with only 37.5% and 39.3% G+C for the 2.475kb and 576bp coding regions, respectively, which is close to the composition of Staphylococcus aureus DNA. Codon usage analysis revealed a preference for A/T bases at the third position of the codons with only 21 % G/C, which is comparable to other structural genes of S. aureus (Wada et al, 1990).
- each repeating unit consists of approx. 384 nucleotides encoding 128 amino acids, and the entire repeating region contains 768 amino acids composed of the six repeated units.
- Sequence analysis revealed that the six repeated units are highly homologous differing only in 11-14 nucleotides of the 384bp, most of which appear at the same nucleotide position within each repeated unit (data not shown). All of the nucleotide differences between the repeated units can be explained by point mutations, and resulted in five to eight amino acid differences between the repeating units comprising the deduced protein sequence.
- a hydropathy profile of the deduced amino acid sequences of ORFl and ORF2 shows the pronounced hydrophilicity of the predicted protein products (Figs 5 and 6). Also shown are the surface probability, antigenic index, and secondary structure generated for each using the software Mac Vector 3.5, which reveal characteristics specific of surface proteins or surface-like proteins.
- ORF 1 and ORF2 predicts pi values of 4.83 and 8.75, and calculated molecular weights of 90,783 daltons (D) and 21,038D, respectively. Both predicted protein products are rich in lysine and proline amino acids, with each making up approx. 13% of the total amino acid sequence in the translated products.
- a BLAST search for amino acid similarities identified homologies of ORFl with neurofilament triplet proteins from human and mouse, collagen alpha type proteins, and the surface associated C protein alpha antigen of group B streptococci (data not shown). It is noteworthy that ORFl has a similar structure to the C alpha antigen gene, which contains nine identical 246 nucleotide tandem repeating units. The shared similarities between the C alpha antigen protein and ORFl encompassed the repeated region, with 26% amino acids identical, and 18% conservative substitutions over a region of 642 amino acids.
- ORF2 amino acid sequence showed weak homology to proline-rich proteins such as sporozoite surface protein 2 from Plasmodium yoelii, neurofilament triplet M protein from chicken, and a glutamic acid-specific endopeptidase from S. aureus (data not shown).
- ORF1 and pGEX-ORF2 respectively. Induction of the lac promoter of the expression plasmids results in high level expression of a fusion protein in each case.
- the recombinant fusion proteins produced in Example 13 and subsequently cleaved using thrombin are used to elicit antibodies in rabbits.
- Antigen preparations are formulated with 0, 10 or lOO ⁇ g protein in incomplete Freund's adjuvant (IF A; 1:1, oil:water).
- Animal hosts, preferably rabbits are injected intramuscularly (i/m) (1ml) into the left hind leg for the primary inoculation and 4 weeks later boosted with an i/m injection of the same preparation into the right hind leg.
- Sera are collected from all animals before the primary inoculations and then at weekly intervals until 4 weeks post secondary inoculation. Sera are stored at -20 °C until assayed for antibodies using the enzyme immunoassay (EIA) described below. Pre-bleed sera from all animals are screened for antibodies to the polypeptides prior to the commencement of experiments and any animals demonstrating significant antibody levels thereto (i.e. EIA OD > 0.2 at 1/300 serum dilution) are excluded.
- EIA enzyme immunoassay
- thrombin cleaved protein purified from the GST moiety, is bound to 96-well microtitre plates (Nunc Maxisorb) by incubating 0.2 ⁇ g per well in lOO ⁇ l of 50mM carbonate buffer (pH 9.6) for 20hrs at 20°C. The plates are then post-coated (lhr at 20°C) with lOO ⁇ l per well of phosphate buffered saline (PBS: 0.9% w/v, pH 7.2) containing 1% (w/v) sodium casein.
- PBS phosphate buffered saline
- PBST phosphate buffered saline containing 0.05% (v/v) Tween 20
- lOO ⁇ l of serial dilutions of serum samples are added to the wells for lhr at 20 D C.
- the plates are then washed 4 times with PBST before the addition of lOO ⁇ l per well of a 1/1000 dilution of horseradish peroxidase conjugated anti-ORFl or anti- ORF2 polypeptide IgG in PBST for 1 hr at 20°C.
- TMB tetra-methyl benzidine
- Soluble protein extracts obtained from several clonal pathogenic and commensal isolates of Staphylococcus aureus are screened by ELISA as described in Example 15, using antibodies derived from Example 14, which are capable of binding to the polypeptides encoded by ORFl (SEQ ID NO:2) and ORF2 (SEQ ID NO:3).
- MOLECULE TYPE DNA (genomic)
- ORGANISM Staphylococcus aureus
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96915919A EP0833918A1 (en) | 1995-06-13 | 1996-06-13 | Nucleic acid molecule and its uses in determining pathogenicity of staphylococcus |
AU58884/96A AU5888496A (en) | 1995-06-13 | 1996-06-13 | Nucleic acid molecule and its uses in determining pathogenic ity of staphylococcus |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPN3507 | 1995-06-13 | ||
AUPN3507A AUPN350795A0 (en) | 1995-06-13 | 1995-06-13 | Nucleic acid molecule and its uses in determining pathogenicity of Staphylococcus |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996041878A1 true WO1996041878A1 (en) | 1996-12-27 |
Family
ID=3787848
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU1996/000353 WO1996041878A1 (en) | 1995-06-13 | 1996-06-13 | Nucleic acid molecule and its uses in determining pathogenicity of staphylococcus |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0833918A1 (en) |
AU (1) | AUPN350795A0 (en) |
WO (1) | WO1996041878A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0837131A2 (en) * | 1996-10-17 | 1998-04-22 | Smithkline Beecham Corporation | Staphylococcus fibronectin binding protein compounds |
DE19731292A1 (en) * | 1997-07-21 | 1999-01-28 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Nucleic Acid Molecule, Kit, and Use |
WO2000043418A1 (en) * | 1999-01-26 | 2000-07-27 | Smithkline Beecham Corporation | Bira |
US6376186B1 (en) | 1999-05-03 | 2002-04-23 | Gen-Probe Incorporated | Polynucleotide probes for detection and quantitation of staphylococcus |
US6821770B1 (en) | 1999-05-03 | 2004-11-23 | Gen-Probe Incorporated | Polynucleotide matrix-based method of identifying microorganisms |
WO2012145450A1 (en) * | 2011-04-22 | 2012-10-26 | 3M Innovative Properties Company | Luminescence detection method |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986002358A1 (en) * | 1984-10-19 | 1986-04-24 | Technology Licence Company Limited | Monoclonal antibodies and their use |
AU4513593A (en) * | 1992-07-07 | 1994-01-31 | Fuso Pharmaceutical Industries, Ltd. | Probe for diagnosing infectious disease |
WO1994014444A1 (en) * | 1992-12-24 | 1994-07-07 | Otsuka Pharmaceutical Co., Ltd. | Psoriasis remedy |
WO1995034655A2 (en) * | 1994-06-07 | 1995-12-21 | The Rockefeller University | Surface protein of staphylococcus aureus |
EP0694309A2 (en) * | 1994-07-29 | 1996-01-31 | The Kitasato Institute | Vaccine, antigens and antibodies containing compound for inhibiting and preventing induced staphylococcus infection |
WO1996008582A2 (en) * | 1994-09-12 | 1996-03-21 | Bergeron Michel G | Specific and universal probes and amplification primers to rapidly detect and identify common bacterial pathogens and antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories |
-
1995
- 1995-06-13 AU AUPN3507A patent/AUPN350795A0/en not_active Abandoned
-
1996
- 1996-06-13 WO PCT/AU1996/000353 patent/WO1996041878A1/en not_active Application Discontinuation
- 1996-06-13 EP EP96915919A patent/EP0833918A1/en not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986002358A1 (en) * | 1984-10-19 | 1986-04-24 | Technology Licence Company Limited | Monoclonal antibodies and their use |
AU4513593A (en) * | 1992-07-07 | 1994-01-31 | Fuso Pharmaceutical Industries, Ltd. | Probe for diagnosing infectious disease |
WO1994014444A1 (en) * | 1992-12-24 | 1994-07-07 | Otsuka Pharmaceutical Co., Ltd. | Psoriasis remedy |
WO1995034655A2 (en) * | 1994-06-07 | 1995-12-21 | The Rockefeller University | Surface protein of staphylococcus aureus |
EP0694309A2 (en) * | 1994-07-29 | 1996-01-31 | The Kitasato Institute | Vaccine, antigens and antibodies containing compound for inhibiting and preventing induced staphylococcus infection |
WO1996008582A2 (en) * | 1994-09-12 | 1996-03-21 | Bergeron Michel G | Specific and universal probes and amplification primers to rapidly detect and identify common bacterial pathogens and antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories |
Non-Patent Citations (5)
Title |
---|
E. JAWETZ et al., "Review of Medical Microbiology", 15th Edition, 1982, pages 146-154 and 189-193. * |
FEMS SYMP., (1988), 40, T.J. FOSTER et al., "Genetic Analysis of Staphylococcus Aureus Virulence"; & IMMUNOCHEM. MOL. GENET. ANAL. BACT. PATHOG., 103-119. * |
J.G. HOLT (Editor-In-Chief): Bergey's Manual R of Systematic Bacteriology, Volume 2, 1986, pages 1013-1019. * |
NUCLEIC ACIDS RESEARCH, Vol. 18, No. 24, 1990, J. WELSH & M. McCLELLAND: "Fingerprinting Genomes Using PCR with Arbitary Primers", 7213-7218. * |
ZENTRALBL. BAKTERIOL., Suppl. (1994), 27, T.J. FOSTER & D. McDEVITT, "Genetic Analysis of Staphylococcus Aureus Virulence"; & MOLECULAR PATHOGENESIS OF SURGICAL INFECTIONS, 11-29. * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6461614B1 (en) | 1996-10-17 | 2002-10-08 | Smithkline Beecham Corporation | Fibronectin binding proteins |
EP0837131A3 (en) * | 1996-10-17 | 2000-01-12 | Smithkline Beecham Corporation | Staphylococcus fibronectin binding protein compounds |
EP0837131A2 (en) * | 1996-10-17 | 1998-04-22 | Smithkline Beecham Corporation | Staphylococcus fibronectin binding protein compounds |
DE19731292A1 (en) * | 1997-07-21 | 1999-01-28 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Nucleic Acid Molecule, Kit, and Use |
WO2000043418A1 (en) * | 1999-01-26 | 2000-07-27 | Smithkline Beecham Corporation | Bira |
US6448038B1 (en) | 1999-01-26 | 2002-09-10 | Smithkline Beecham Corporation | BirA from staphylococcus aureus |
US6376186B1 (en) | 1999-05-03 | 2002-04-23 | Gen-Probe Incorporated | Polynucleotide probes for detection and quantitation of staphylococcus |
US6821770B1 (en) | 1999-05-03 | 2004-11-23 | Gen-Probe Incorporated | Polynucleotide matrix-based method of identifying microorganisms |
US7449328B2 (en) | 1999-05-03 | 2008-11-11 | Gen-Probe Incorporated | Probe matrix-based device for identifying microorganisms |
WO2012145450A1 (en) * | 2011-04-22 | 2012-10-26 | 3M Innovative Properties Company | Luminescence detection method |
US8852894B2 (en) | 2011-04-22 | 2014-10-07 | 3M Innovative Properties Company | Luminescence detection method |
US9845498B2 (en) | 2011-04-22 | 2017-12-19 | 3M Innovative Properties Company | Luminescence detection method |
EP3287765A1 (en) * | 2011-04-22 | 2018-02-28 | 3M Innovative Properties Company | Luminescence detection method |
Also Published As
Publication number | Publication date |
---|---|
EP0833918A1 (en) | 1998-04-08 |
AUPN350795A0 (en) | 1995-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Marr et al. | Characterization of novel type C staphylococcal enterotoxins: biological and evolutionary implications | |
Cockayne et al. | Molecular cloning of a 32-kilodalton lipoprotein component of a novel iron-regulated Staphylococcus epidermidis ABC transporter | |
CA2254853C (en) | Compositions and methods for screening antimicrobials | |
JP4714342B2 (en) | Polypeptides and polynucleotides derived from coagulase negative Staphylococcus | |
US6617441B1 (en) | Diagnostic test for borrelia infection | |
US7723087B2 (en) | Nucleic acid molecules for enhanced production of a bacterial polysaccharide and methods of use thereof | |
AU2007200937A1 (en) | Antigenic polypeptides | |
CA2179149A1 (en) | Methods and materials for the detection of staphylococcus aureus | |
US7160990B2 (en) | Antibodies to a fibrinogen binding protein of staphylococcus epidermidis | |
WO1996041878A1 (en) | Nucleic acid molecule and its uses in determining pathogenicity of staphylococcus | |
EP0917471B1 (en) | Treatment and diagnosis of infections of gram positive cocci | |
JP2001522605A5 (en) | ||
EP0726314A1 (en) | FIMBRILLIN PROTEIN OF $i(PORPHYROMONAS GINGIVALIS) | |
US5556755A (en) | Method for detecting Branhamella catarrhalis | |
US6204003B1 (en) | Methods for the diagnosis of feline infectious anemia | |
US5585465A (en) | Isolated toxin associated with Kawasaki syndrome | |
AU774293B2 (en) | Compositions and methods for screening antimicrobials | |
EP0650524A1 (en) | Cytolysin gene and gene product | |
FOOTNOTE | The eap Gene as a Novel Target for Specific Identification of Staphylococcus aureus | |
AU2004203421A1 (en) | Polypeptides and polynucleotides from coagulase-negative staphylococci | |
MXPA98004261A (en) | Therapeutic compositions and diagnosti |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1997 973664 Date of ref document: 19971213 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996915919 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1996915919 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996915919 Country of ref document: EP |